Solasia Pharma K.K. Reports Consolidated Earnings Results for the Nine Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending December 31, 2019
The company provided consolidated earnings guidance for the year ending December 31, 2019. For the year, the company expects net sales in the range of JPY 500 million to JPY 1,700 million, operating loss in the range of JPY 3,000 million to JPY 2,000 million, loss in the range of JPY 3,000 million to JPY 2,000 million and basic loss per share of JPY 28.54 to JPY 19.02.